☆ 4.8 Article

COVID-19 vaccination and Atypical hemolytic uremic syndrome

FRONTIERS IN IMMUNOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Urology & Nephrology

Atypical Hemolytic Uremic Syndrome Occurring After Receipt of mRNA-1273 COVID-19 Vaccine Booster: A Case Report

Kathleen J. Claes et al.

Summary: We report a case of a previously healthy 38-year-old woman who developed atypical hemolytic uremic syndrome (aHUS) after receiving a booster dose of an mRNA COVID-19 vaccine. The patient experienced symptoms of headache, nausea, and general malaise, and was diagnosed with thrombotic microangiopathy (TMA). Treatment included blood pressure control, hemodialysis, plasma exchange, and respiratory support, and kidney function improved with the initiation of eculizumab therapy. Genetic analysis identified a pathogenic variant in complement C3. Based on the timing, we hypothesize that the vaccine was likely the trigger for aHUS development in this patient.

AMERICAN JOURNAL OF KIDNEY DISEASES (2023)

Add to Collection

Article Biology

Vaccine-induced COVID-19 mimicry syndrome

Eric Kowarz et al.

Summary: A global vaccination campaign is underway to immunize billions of people against the COVID-19 pandemic. However, rare cases of severe side effects, such as cerebral venous sinus thrombosis (CVST), have been reported after vaccination with adenoviral vector-based vaccines. These events have not been observed with mRNA-based vaccines. Scientists have proposed a mechanism called vaccine-induced immune thrombotic thrombocytopenia (VITT) and discovered that DNA-encoded Spike protein can be spliced in a way that leads to the secretion of potentially harmful Spike variants. Avoiding such splicing events is important for the safety of future vaccines.

ELIFE (2022)

Add to Collection

Article Hematology

SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura

Hridaya Shah et al.

BLOOD (2022)

Add to Collection

Article Hematology

Complement dysregulation is associated with severe COVID-19 illness

Jia Yu et al.

Summary: The serum of COVID-19 patients can induce complement-mediated cell death and is associated with dysregulation of APC, which may contribute to the pathogenesis and severity of the disease.

HAEMATOLOGICA (2022)

Add to Collection

Letter Medicine, General & Internal

Immune thrombocytopenia following COVID-19 mRNA vaccine: casuality or causality?

Federico Pasin et al.

INTERNAL AND EMERGENCY MEDICINE (2022)

Add to Collection

Article Urology & Nephrology

A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination

Mark Canney et al.

Summary: This population-level cohort study found that the second or third dose of COVID-19 vaccine was associated with higher relative risk but low absolute increased risk of glomerular disease relapse.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Add to Collection

Article Immunology

Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report

Romana Rysava et al.

Summary: Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by dysregulation in the alternative complement activation pathway. It is a life-threatening condition that typically causes acute kidney injury. Genetic mutations and factors like viral or bacterial infections can trigger the disease, and eculizumab is an effective treatment method.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Urology & Nephrology

Atypical Hemolytic Uremic Syndrome after ChAdOx1 nCoV-19 Vaccination in a Patient with Homozygous CFHR3/CFHR1 Gene Deletion

Francisco Ferrer et al.

Summary: Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy affecting the kidneys, while atypical HUS involves genetic or acquired dysregulation of the complement alternative pathway. The patient in the case experienced symptoms after vaccination with ChAdOx1 nCoV-19, leading to a clinical presentation of aHUS.

NEPHRON (2022)

Add to Collection

Editorial Material Urology & Nephrology

Atypical Hemolytic and Uremic Syndrome Triggered by Infection With SARS-CoV2

Jessica Kaufeld et al.

KIDNEY INTERNATIONAL REPORTS (2021)

Add to Collection

Article Hematology

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Fadi Fakhouri et al.

Summary: The study on eculizumab discontinuation in patients with atypical hemolytic uremic syndrome (aHUS) showed that a strategy based on complement genetics is reasonable and safe, improving patient management and quality of life while reducing treatment costs.

BLOOD (2021)

Add to Collection

Article Hematology

Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia

Andreas Greinacher et al.

Summary: The mechanism underlying vaccine-induced immune thrombotic thrombocytopenia (VITT) primarily involves the formation of PF4/vaccine complexes and the proinflammatory environment stimulated by the vaccine, leading to the production of high-titer anti-PF4 antibodies in the body and consequent thrombosis.

BLOOD (2021)

Add to Collection

Letter Urology & Nephrology

Atypical HUS relapse triggered by COVID-19

Simon Ville et al.

KIDNEY INTERNATIONAL (2021)

Add to Collection

Article Urology & Nephrology

First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine - case report

Bilgin Osmanodja et al.

Summary: This case describes a 25-year-old male patient developing aTTP after receiving the mRNA-based Spikevax vaccine. Despite presenting symptoms 13 days post-vaccination, the patient's condition improved with treatment, suggesting the vaccine may have acted as a trigger for underlying TTP.

BMC NEPHROLOGY (2021)

Add to Collection

Review Immunology

Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature

Bruno Fattizzo et al.

Summary: The complex relationship between SARS-CoV-2 infection and complement activation is actively being investigated, with exacerbations of complement-mediated diseases occurring during COVID-19 infection. Hemolytic episodes in conditions like PNH, AIHA, CAD, and HUS may benefit from complement inhibitors. Severe hemolytic exacerbations during COVID-19 infection may require greater therapeutic intervention compared to those after SARS-CoV-2 vaccination, highlighting the importance of vaccination in this patient population. Treatment choices should be based on the severity of hemolysis and COVID-19 infection, with options including transfusions, complement inhibitors, steroids, rituximab, plasma exchange, hemodialysis, and anti-thrombotic prophylaxis.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Hematology

COVID-19 as a potential trigger of complement-mediated atypical HUS

Carine El Sissy et al.

BLOOD (2021)

Add to Collection

Review Infectious Diseases

SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies

Ahmed M. Almehdi et al.

Summary: The study highlights the distinct structural features of the SARS-CoV-2 S protein, its crucial role in pathogenesis, and its potential in developing therapies and vaccines. Understanding the significance of the S protein in viral infection and the development of therapeutic compounds and vaccines may lead to a significant reduction in the global health burden of the COVID-19 pandemic, although the efficacy and safety of these treatments remain debated.

INFECTION (2021)

Add to Collection

Review Clinical Neurology

Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review

Maryam Sharifian-Dorche et al.

Summary: CVST and VITT are rare but severe complications following COVID-19 vaccination, with most patients being female. Symptoms typically occur within one week after vaccination, with headache being the primary presenting symptom. Some patients may experience serious complications such as intracerebral hemorrhage.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

Add to Collection

Article Immunology

Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality

Federica Defendi et al.

Summary: The study analyzed the complement activation pathways and components in COVID-19 patients, identifying two distinct patient clusters: one with activation of alternative and lectin pathways, low antigenic levels of complement components, and higher mortality and need for oxygen or ICU care; the other with high classical pathway activity, higher antigenic levels of complement components, lower need for ICU care, and no deaths.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways

Ralf Kircheis

Summary: The global pandemic of the novel coronavirus has led to the approval and application of various vaccines, but some rare blood clot side effects have been reported, potentially correlated with interactions between vaccine components and the immune system.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Allergy

Complement activation in patients with COVID-19: A novel therapeutic target

Massimo Cugno et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Medical Laboratory Technology

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Cynthia Magro et al.

TRANSLATIONAL RESEARCH (2020)

Add to Collection

Letter Hematology

Complement C5 inhibition in patients with COVID-19-a promising target?

Regis Peffault de Latour et al.

HAEMATOLOGICA (2020)

Add to Collection

Article Hematology

Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition

Jia Yu et al.

BLOOD (2020)

Add to Collection

Review Pediatrics

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use

Kioa L. Wijnsma et al.

PEDIATRIC NEPHROLOGY (2019)

Add to Collection

Review Medicine, General & Internal

Haemolytic uraemic syndrome

Fadi Fakhouri et al.

LANCET (2017)

Add to Collection

Review Pediatrics

An international consensus approach to the management of atypical hemolytic uremic syndrome in children

Chantal Loirat et al.

PEDIATRIC NEPHROLOGY (2016)

Add to Collection

Review Medicine, General & Internal

Syndromes of Thrombotic Microangiopathy

James N. George et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Medicine, General & Internal

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome

C. M. Legendre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Pediatrics

Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics

Lianne M. Geerdink et al.

PEDIATRIC NEPHROLOGY (2012)

Add to Collection

Review Genetics & Heredity

Atypical hemolytic uremic syndrome

Chantal Loirat et al.

ORPHANET JOURNAL OF RARE DISEASES (2011)

Add to Collection

Article Urology & Nephrology

Clinical Features of Anti-Factor H Autoantibody-Associated Hemolytic Uremic Syndrome

Marie-Agnes Dragon-Durey et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)

Add to Collection

Article Biochemistry & Molecular Biology

Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32

J Esparza-Gordillo et al.

HUMAN MOLECULAR GENETICS (2005)

Add to Collection

Article Biochemistry & Molecular Biology

Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease

J Caprioli et al.

HUMAN MOLECULAR GENETICS (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.